Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2010

Open Access 01-12-2010 | Research

Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines

Authors: Stefan Nagel, Letizia Venturini, Victor E Marquez, Corinna Meyer, Maren Kaufmann, Michaela Scherr, Roderick AF MacLeod, Hans G Drexler

Published in: Molecular Cancer | Issue 1/2010

Login to get access

Abstract

Background

NK- and T-cells are closely related lymphocytes, originating from the same early progenitor cells during hematopoiesis. In these differentiation processes deregulation of developmental genes may contribute to leukemogenesis. Here, we compared expression profiles of NK- and T-cell lines for identification of aberrantly expressed genes in T-cell acute lymphoblastic leukemia (T-ALL) which physiologically regulate the differentiation program of the NK-cell lineage.

Results

This analysis showed high expression levels of HOXA9, HOXA10 and ID2 in NK-cell lines in addition to T-cell line LOUCY, suggesting leukemic deregulation therein. Overexpression experiments, chromatin immuno-precipitation and promoter analysis demonstrated that HOXA9 and HOXA10 directly activated expression of ID2. Concomitantly elevated expression levels of HOXA9 and HOXA10 together with ID2 in cell lines containing MLL translocations confirmed this form of regulation in both ALL and acute myeloid leukemia. Overexpression of HOXA9, HOXA10 or ID2 resulted in repressed expression of apoptosis factor BIM. Furthermore, profiling data of genes coding for chromatin regulators of homeobox genes, including components of polycomb repressor complex 2 (PRC2), indicated lacking expression of EZH2 in LOUCY and exclusive expression of HOP in NK-cell lines. Subsequent treatment of T-cell lines JURKAT and LOUCY with DZNep, an inhibitor of EZH2/PRC2, resulted in elevated and unchanged HOXA9/10 expression levels, respectively. Moreover, siRNA-mediated knockdown of EZH2 in JURKAT enhanced HOXA10 expression, confirming HOXA10-repression by EZH2. Additionally, profiling data and overexpression analysis indicated that reduced expression of E2F cofactor TFDP1 contributed to the lack of EZH2 in LOUCY. Forced expression of HOP in JURKAT cells resulted in reduced HOXA10 and ID2 expression levels, suggesting enhancement of PRC2 repression.

Conclusions

Our results show that major differentiation factors of the NK-cell lineage, including HOXA9, HOXA10 and ID2, were (de)regulated via PRC2 which therefore contributes to T-cell leukemogenesis.
Appendix
Available only for authorised users
Literature
1.
Huntington ND, Vosshenrich CA, Di Santo JP: Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol. 2007, 7: 703-714. 10.1038/nri2154CrossRefPubMed
2.
Anderson MK: At the crossroads: diverse roles of early thymocyte transcriptional regulators. Immunol Rev. 2006, 209: 191-211. 10.1111/j.0105-2896.2006.00352.xCrossRefPubMed
3.
4.
Rothenberg EV, Dionne CJ: Lineage plasticity and commitment in T-cell development. Immunol Rev. 2002, 187: 96-115. 10.1034/j.1600-065X.2002.18709.xCrossRefPubMed
5.
O'Neil J, Shank J, Cusson N, Murre C, Kelliher M: TAL1/SCL induces leukemia by inhibiting the transcriptional activity of E47/HEB. Cancer Cell. 2004, 5: 587-596. 10.1016/j.ccr.2004.05.023CrossRefPubMed
6.
Zhong Y, Jiang L, Hiai H, Toyokuni S, Yamada Y: Overexpression of a transcription factor LYL1 induces T- and B-cell lymphoma in mice. Oncogene. 2007, 26: 6937-6947. 10.1038/sj.onc.1210494CrossRefPubMed
7.
Bain G, Engel I, Robanus Maandag EC, te Riele HP, Voland JR, Sharp LL, Chun J, Huey B, Pinkel D, Murre C: E2A deficiency leads to abnormalities in alphabeta T-cell development and to rapid development of T-cell lymphomas. Mol Cell Biol. 1997, 17: 4782-4791.PubMedCentralCrossRefPubMed
8.
Yokota Y, Mansouri A, Mori S, Sugawara S, Adachi S, Nishikawa S, Gruss P: Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature. 1999, 397: 702-706. 10.1038/17812CrossRefPubMed
9.
Boos MD, Yokota Y, Eberl G, Kee BL: Mature natural killer cell and lymphoid tissue-inducing cell development requires Id2-mediated suppression of E protein activity. J Exp Med. 2007, 204: 1119-1130. 10.1084/jem.20061959PubMedCentralCrossRefPubMed
10.
Morrow MA, Mayer EW, Perez CA, Adlam M, Siu G: Overexpression of the Helix-Loop-Helix protein Id2 blocks T cell development at multiple stages. Mol Immunol. 1999, 36: 491-503. 10.1016/S0161-5890(99)00071-1CrossRefPubMed
11.
Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ: Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science. 1991, 253: 79-82. 10.1126/science.1676542CrossRefPubMed
12.
Bernard OA, Busson-LeConiat M, Ballerini P, Mauchauffé M, Della Valle V, Monni R, Nguyen Khac F, Mercher T, Penard-Lacronique V, Pasturaud P, Gressin L, Heilig R, Daniel MT, Lessard M, Berger R: A new recurrent and specific cryptic translocation, t(5;14)(q35;q32), is associated with expression of the Hox11L2 gene in T acute lymphoblastic leukemia. Leukemia. 2001, 15: 1495-1504. 10.1038/sj.leu.2402249CrossRefPubMed
13.
Nagel S, Kaufmann M, Drexler HG, MacLeod RA: The cardiac homeobox gene NKX2-5 is deregulated by juxtaposition with BCL11B in pediatric T-ALL cell lines via a novel t(5;14)(q35.1;q32.2). Cancer Res. 2003, 63: 5329-5334.PubMed
14.
Soulier J, Clappier E, Cayuela JM, Regnault A, García-Peydró M, Dombret H, Baruchel A, Toribio ML, Sigaux F: HOXA genes are included in genetic and biologic networks defining human acute T-cell leukemia (T-ALL). Blood. 2005, 106: 274-286. 10.1182/blood-2004-10-3900CrossRefPubMed
15.
Speleman F, Cauwelier B, Dastugue N, Cools J, Verhasselt B, Poppe B, Van Roy N, Vandesompele J, Graux C, Uyttebroeck A, Boogaerts M, De Moerloose B, Benoit Y, Selleslag D, Billiet J, Robert A, Huguet F, Vandenberghe P, De Paepe A, Marynen P, Hagemeijer A: A new recurrent inversion, inv(7)(p15q34), leads to transcriptional activation of HOXA10 and HOXA11 in a subset of T-cell acute lymphoblastic leukemias. Leukemia. 2005, 19: 358-366. 10.1038/sj.leu.2403657CrossRefPubMed
16.
Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ: MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet. 2002, 30: 41-47. 10.1038/ng765CrossRefPubMed
17.
Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT: Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. Blood. 2003, 102: 262-268. 10.1182/blood-2002-10-3221CrossRefPubMed
18.
Quentmeier H, Dirks WG, Macleod RA, Reinhardt J, Zaborski M, Drexler HG: Expression of HOX genes in acute leukemia cell lines with and without MLL translocations. Leuk Lymphoma. 2004, 45: 567-574. 10.1080/10428190310001609942CrossRefPubMed
19.
Nakamura T, Mori T, Tada S, Krajewski W, Rozovskaia T, Wassell R, Dubois G, Mazo A, Croce CM, Canaani E: ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell. 2002, 10: 1119-1128. 10.1016/S1097-2765(02)00740-2CrossRefPubMed
20.
Dou Y, Milne TA, Ruthenburg AJ, Lee S, Lee JW, Verdine GL, Allis CD, Roeder RG: Regulation of MLL1 H3K4 methyltransferase activity by its core components. Nat Struct Mol Biol. 2006, 13: 713-719. 10.1038/nsmb1128CrossRefPubMed
21.
Van Vlierberghe P, van Grotel M, Tchinda J, Lee C, Beverloo HB, van der Spek PJ, Stubbs A, Cools J, Nagata K, Fornerod M, Buijs-Gladdines J, Horstmann M, van Wering ER, Soulier J, Pieters R, Meijerink JP: The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood. 2008, 111: 4668-4680. 10.1182/blood-2007-09-111872PubMedCentralCrossRefPubMed
22.
Sparmann A, van Lohuizen M: Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer. 2006, 6: 846-856. 10.1038/nrc1991CrossRefPubMed
23.
Schwartz YB, Pirrotta V: Polycomb complexes and epigenetic states. Curr Opin Cell Biol. 2008, 20: 266-273. 10.1016/j.ceb.2008.03.002CrossRefPubMed
24.
Klymenko T, Müller J: The histone methyltransferases Trithorax and Ash1 prevent transcriptional silencing by Polycomb group proteins. EMBO Rep. 2004, 5: 373-377. 10.1038/sj.embor.7400111PubMedCentralCrossRefPubMed
25.
Czermin B, Melfi R, McCabe D, Seitz V, Imhof A, Pirrotta V: Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell. 2002, 111: 185-196. 10.1016/S0092-8674(02)00975-3CrossRefPubMed
26.
Müller J, Hart CM, Francis NJ, Vargas ML, Sengupta A, Wild B, Miller EL, O'Connor MB, Kingston RE, Simon JA: Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell. 2002, 111: 197-208. 10.1016/S0092-8674(02)00976-5CrossRefPubMed
27.
Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. Braunschweig. 2005, (compact disc).
28.
Nagel S, Burek C, Venturini L, Scherr M, Quentmeier H, Meyer C, Rosenwald A, Drexler HG, MacLeod RA: Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood. 2007, 109: 3015-3023.PubMed
29.
Nagel S, Venturini L, Przybylski GK, Grabarczyk P, Schmidt CA, Meyer C, Drexler HG, Macleod RA, Scherr M: Activation of miR-17-92 by NK-like homeodomain proteins suppresses apoptosis via reduction of E2F1 in T-cell acute lymphoblastic leukemia. Leuk Lymphoma. 2009, 50: 101-108. 10.1080/10428190802626632CrossRefPubMed
30.
Nagel S, Venturini L, Meyer C, Kaufmann M, Scherr M, Drexler HG, MacLeod RA: Multiple mechanisms induce ectopic expression of LYL1 in subsets of T-ALL cell lines. Leuk Res. 2010, 34: 521-528. 10.1016/j.leukres.2009.06.020CrossRefPubMed
31.
MacLeod RA, Kaufmann M, Drexler HG: Cytogenetic harvesting of commonly used tumor cell lines. Nat Protoc. 2007, 2: 372-382. 10.1038/nprot.2007.29CrossRefPubMed
32.
Scherr M, Battmer K, Blömer U, Schiedlmeier B, Ganser A, Grez M, Eder M: Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood. 2002, 99: 709-712. 10.1182/blood.V99.2.709CrossRefPubMed
33.
Rahman MA, Li M, Li P, Wang H, Dey SK, Das SK: Hoxa-10 deficiency alters region-specific gene expression and perturbs differentiation of natural killer cells during decidualization. Dev Biol. 2006, 290: 105-117. 10.1016/j.ydbio.2005.11.016PubMedCentralCrossRefPubMed
34.
Watkins NA, Gusnanto A, de Bono B, De S, Miranda-Saavedra D, Hardie DL, Angenent WG, Attwood AP, Ellis PD, Erber W, Foad NS, Garner SF, Isacke CM, Jolley J, Koch K, Macaulay IC, Morley SL, Rendon A, Rice KM, Taylor N, Thijssen-Timmer DC, Tijssen MR, van der Schoot CE, Wernisch L, Winzer T, Dudbridge F, Buckley CD, Langford CF, Teichmann S, Göttgens B, Ouwehand WH, : A HaemAtlas: characterizing gene expression in differentiated human blood cells. Blood. 2009, 113: e1-9. 10.1182/blood-2008-06-162958PubMedCentralCrossRefPubMed
35.
Zhao FQ, Sheng ZM, Tsai MM, Hubbs AE, Wang R, O'Leary TJ, Izon DJ, Taubenberger JK: Serial analysis of gene expression in murine fetal thymocyte cell lines. Int Immunol. 2002, 14: 1383-1395. 10.1093/intimm/dxf103CrossRefPubMed
36.
Vaillant F, Blyth K, Andrew L, Neil JC, Cameron ER : Enforced expression of Runx2 perturbs T cell development at a stage coincident with beta-selection. J Immunol. 2002, 169: 2866-2874.CrossRefPubMed
37.
Hassan MQ, Tare R, Lee SH, Mandeville M, Weiner B, Montecino M, van Wijnen AJ, Stein JL, Stein GS, Lian JB: HOXA10 controls osteoblastogenesis by directly activating bone regulatory and phenotypic genes. Mol Cell Biol. 2007, 27: 3337-3352. 10.1128/MCB.01544-06PubMedCentralCrossRefPubMed
38.
Schwartz R, Engel I, Fallahi-Sichani M, Petrie HT, Murre C: Gene expression patterns define novel roles for E47 in cell cycle progression, cytokine-mediated signaling, and T lineage development. Proc Natl Acad Sci USA. 2006, 103: 9976-9981. 10.1073/pnas.0603728103PubMedCentralCrossRefPubMed
39.
Cao R, Wang L, Wang H, Xia L, Erdjument-Bromage H, Tempst P, Jones RS, Zhang Y: Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science. 2002, 298: 1039-1043. 10.1126/science.1076997CrossRefPubMed
40.
Boyer LA, Plath K, Zeitlinger J, Brambrink T, Medeiros LA, Lee TI, Levine SS, Wernig M, Tajonar A, Ray MK, Bell GW, Otte AP, Vidal M, Gifford DK, Young RA, Jaenisch R: Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature. 2006, 441: 349-353. 10.1038/nature04733CrossRefPubMed
41.
Papp B, Müller J: Histone trimethylation and the maintenance of transcriptional ON and OFF states by trxG and PcG proteins. Genes Dev. 2006, 20: 2041-2054. 10.1101/gad.388706PubMedCentralCrossRefPubMed
42.
Petruk S, Smith ST, Sedkov Y, Mazo A: Association of trxG and PcG proteins with the bxd maintenance element depends on transcriptional activity. Development. 2008, 135: 2383-2390. 10.1242/dev.023275CrossRefPubMed
43.
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q: Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev. 2007, 21: 1050-1063. 10.1101/gad.1524107PubMedCentralCrossRefPubMed
44.
Umlauf D, Goto Y, Cao R, Cerqueira F, Wagschal A, Zhang Y, Feil R: Imprinting along the Kcnq1 domain on mouse chromosome 7 involves repressive histone methylation and recruitment of Polycomb group complexes. Nat Genet. 2004, 36: 1296-1300. 10.1038/ng1467CrossRefPubMed
45.
Pandey RR, Mondal T, Mohammad F, Enroth S, Redrup L, Komorowski J, Nagano T, Mancini-Dinardo D, Kanduri C: Kcnq1ot1 antisense noncoding RNA mediates lineage-specific transcriptional silencing through chromatin-level regulation. Mol Cell. 2008, 32 (2): 232-246. 10.1016/j.molcel.2008.08.022CrossRefPubMed
46.
Cha TL, Zhou BP, Xia W, Wu Y, Yang CC, Chen CT, Ping B, Otte AP, Hung MC: Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine 27 in histone H3. Science. 2005, 310: 306-310. 10.1126/science.1118947CrossRefPubMed
47.
Kee HJ, Kim JR, Nam KI, Park HY, Shin S, Kim JC, Shimono Y, Takahashi M, Jeong MH, Kim N, Kim KK, Kook H: Enhancer of polycomb1, a novel homeodomain only protein-binding partner, induces skeletal muscle differentiation. J Biol Chem. 2007, 282: 7700-7709. 10.1074/jbc.M611198200CrossRefPubMed
48.
Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Möller P, Stilgenbauer S, Pollack JR, Wirth T: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008, 112: 4202-4212. 10.1182/blood-2008-03-147645CrossRefPubMed
49.
Varambally S, Cao Q, Mani RS, Shankar S, Wang X, Ateeq B, Laxman B, Cao X, Jing X, Ramnarayanan K, Brenner JC, Yu J, Kim JH, Han B, Tan P, Kumar-Sinha C, Lonigro RJ, Palanisamy N, Maher CA, Chinnaiyan AM: Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008, 322: 1695-1699. 10.1126/science.1165395PubMedCentralCrossRefPubMed
50.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J. 2003, 22: 5323-5335. 10.1093/emboj/cdg542PubMedCentralCrossRefPubMed
51.
Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C, Harlow E: Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 1993, 7: 1850-1861. 10.1101/gad.7.10.1850CrossRefPubMed
52.
Vijapurkar U, Fischbach N, Shen W, Brandts C, Stokoe D, Lawrence HJ, Largman C: Protein kinase C-mediated phosphorylation of the leukemia-associated HOXA9 protein impairs its DNA binding ability and induces myeloid differentiation. Mol Cell Biol. 2004, 24: 3827-3837. 10.1128/MCB.24.9.3827-3837.2004PubMedCentralCrossRefPubMed
53.
Eklund EA, Jalava A, Kakar R: Tyrosine phosphorylation of HoxA10 decreases DNA binding and transcriptional repression during interferon gamma -induced differentiation of myeloid leukemia cell lines. J Biol Chem. 2000, 275: 20117-20126. 10.1074/jbc.M907915199CrossRefPubMed
54.
Gray MJ, Dallas NA, Van Buren G, Xia L, Yang AD, Somcio RJ, Gaur P, Mangala LS, Vivas-Mejia PE, Fan F, Sanguino AM, Gallick GE, Lopez-Berestein G, Sood AK, Ellis LM: Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene. 2008, 27: 7192-7200. 10.1038/onc.2008.356PubMedCentralCrossRefPubMed
55.
Bai G, Sheng N, Xie Z, Bian W, Yokota Y, Benezra R, Kageyama R, Guillemot F, Jing N: Id sustains Hes1 expression to inhibit precocious neurogenesis by releasing negative autoregulation of Hes1. Dev Cell. 2007, 13: 283-297. 10.1016/j.devcel.2007.05.014CrossRefPubMed
56.
Dik WA, Pike-Overzet K, Weerkamp F, de Ridder D, de Haas EF, Baert MR, van der Spek P, Koster EE, Reinders MJ, van Dongen JJ, Langerak AW, Staal FJ: New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. J Exp Med. 2005, 201: 1715-1723. 10.1084/jem.20042524PubMedCentralCrossRefPubMed
57.
Ferrell CM, Dorsam ST, Ohta H, Humphries RK, Derynck MK, Haqq C, Largman C, Lawrence HJ: Activation of stem-cell specific genes by HOXA9 and HOXA10 homeodomain proteins in CD34+ human cord blood cells. Stem Cells. 2005, 23: 644-655. 10.1634/stemcells.2004-0198CrossRefPubMed
58.
Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT: High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia. Blood. 2009, 114: 647-650. 10.1182/blood-2009-02-206722PubMedCentralCrossRefPubMed
59.
Sarma K, Margueron R, Ivanov A, Pirrotta V, Reinberg D: Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27 trimethylation in vivo. Mol Cell Biol. 2008, 28: 2718-2731. 10.1128/MCB.02017-07PubMedCentralCrossRefPubMed
60.
Simon J, Chiang A, Bender W: Ten different Polycomb group genes are required for spatial control of the abdA and AbdB homeotic products. Development. 1992, 114: 493-505.PubMed
61.
Field SJ, Tsai FY, Kuo F, Zubiaga AM, Kaelin WG, Livingston DM, Orkin SH, Greenberg ME: E2F-1 functions in mice to promote apoptosis and suppress proliferation. Cell. 1996, 85: 549-561. 10.1016/S0092-8674(00)81255-6CrossRefPubMed
62.
Attwooll C, Oddi S, Cartwright P, Prosperini E, Agger K, Steensgaard P, Wagener C, Sardet C, Moroni MC, Helin K: A novel repressive E2F6 complex containing the polycomb group protein, EPC1, that interacts with EZH2 in a proliferation-specific manner. J Biol Chem. 2005, 280: 1199-1208. 10.1074/jbc.M412509200CrossRefPubMed
63.
Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, Shashkin P, Charlot JF, Tcherpakov M, Corbett R, Tam A, Varhol R, Smailus D, Moksa M, Zhao Y, Delaney A, Qian H, Birol I, Schein J, Moore R, Holt R, Horsman DE, Connors JM, Jones S, Aparicio S, Hirst M, Gascoyne RD, Marra MA: Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet. 2010, 42: 181-185. 10.1038/ng.518PubMedCentralCrossRefPubMed
64.
Okada Y, Jiang Q, Lemieux M, Jeannotte L, Su L, Zhang Y: Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol. 2006, 8: 1017-1024. 10.1038/ncb1464PubMedCentralCrossRefPubMed
65.
Panagopoulos I, Kerndrup G, Carlsen N, Strömbeck B, Isaksson M, Johansson B: Fusion of NUP98 and the SET binding protein 1 (SETBP1) gene in a paediatric acute T cell lymphoblastic leukaemia with t(11;18)(p15;q12). Br J Haematol. 2007, 136: 294-296. 10.1111/j.1365-2141.2006.06410.xCrossRefPubMed
66.
Adler HT, Nallaseth FS, Walter G, Tkachuk DC: HRX leukemic fusion proteins form a heterocomplex with the leukemia-associated protein SET and protein phosphatase 2A. J Biol Chem. 1997, 272: 28407-28414. 10.1074/jbc.272.45.28407CrossRefPubMed
67.
Xia ZB, Anderson M, Diaz MO, Zeleznik-Le NJ: MLL repression domain interacts with histone deacetylases, the polycomb group proteins HPC2 and BMI-1, and the corepressor C-terminal-binding protein. Proc Natl Acad Sci USA. 2003, 100: 8342-8347. 10.1073/pnas.1436338100PubMedCentralCrossRefPubMed
68.
Kim SY, Levenson JM, Korsmeyer S, Sweatt JD, Schumacher A: Developmental regulation of Eed complex composition governs a switch in global histone modification in brain. J Biol Chem. 2007, 282: 9962-9972. 10.1074/jbc.M608722200CrossRefPubMed
Metadata
Title
Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines
Authors
Stefan Nagel
Letizia Venturini
Victor E Marquez
Corinna Meyer
Maren Kaufmann
Michaela Scherr
Roderick AF MacLeod
Hans G Drexler
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2010
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/1476-4598-9-151

Other articles of this Issue 1/2010

Molecular Cancer 1/2010 Go to the issue

Research

Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway

Review

Roles of Sema4D and Plexin-B1 in tumor progression

Review

Leucine-rich repeat protein PRAME: expression, potential functions and clinical implications for leukaemia

Research

LIMD1 is more frequently altered than RB1 in head and neck squamous cell carcinoma: clinical and prognostic implications

Research

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression

Research

miR-21: an oncomir on strike in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits